Lipocine Depreciation & Amortization Growth & History (LPCN)
Lipocine's depreciation and amortization was $60,782 for fiscal 2025.
View full Lipocine company overviewLipocine annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $60,782 | $19,676 | +47.87% |
| 2024 | 2024-12-31 | $41,106 | $12,445 | +43.42% |
| 2023 | 2023-12-31 | $28,661 | $19,208 | +203.19% |
| 2022 | 2022-12-31 | $9,453 | $9,073 | +2387.63% |
| 2021 | 2021-12-31 | $380 | −$3,174 | −89.31% |
| 2020 | 2020-12-31 | $3,554 | −$11,889 | −76.99% |
| 2019 | 2019-12-31 | $15,443 | −$3,152 | −16.95% |
| 2018 | 2018-12-31 | $18,595 | −$9,775 | −34.46% |
| 2017 | 2017-12-31 | $28,370 | −$3,590 | −11.23% |
| 2016 | 2016-12-31 | $31,960 | $5,239 | +19.61% |
| 2015 | 2015-12-31 | $26,721 | $12,101 | +82.77% |
| 2014 | 2014-12-31 | $14,620 | −$7,147 | −32.83% |
| 2013 | 2013-12-31 | $21,767 | −$20,799 | −48.86% |
| 2012 | 2012-12-31 | $42,566 | — | — |
Lipocine quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14,648 | −$1,460 | −9.06% |
| Q1 2026 | 2026-03-31 | $14,814 | −$756 | −4.86% |
| Q4 2025 | 2025-12-31 | $14,981 | — | — |
| Q3 2025 | 2025-09-30 | $14,123 | $5,612 | +65.94% |
| Q2 2025 | 2025-06-30 | $16,108 | $7,596 | +89.24% |
| Q1 2025 | 2025-03-31 | $15,570 | $7,058 | +82.92% |
| Q3 2024 | 2024-09-30 | $8,511 | $763 | +9.85% |
| Q2 2024 | 2024-06-30 | $8,512 | $421 | +5.20% |
| Q1 2024 | 2024-03-31 | $8,512 | $3,693 | +76.63% |
| Q3 2023 | 2023-09-30 | $7,748 | $5,170 | +200.54% |
| Q2 2023 | 2023-06-30 | $8,091 | $5,513 | +213.85% |
| Q1 2023 | 2023-03-31 | $4,819 | $3,100 | +180.34% |
| Q3 2022 | 2022-09-30 | $2,578 | — | — |
| Q2 2022 | 2022-06-30 | $2,578 | — | — |
| Q1 2022 | 2022-03-31 | $1,719 | $1,719 | — |
| Q1 2021 | 2021-03-31 | $0 | −$799 | — |
| Q3 2020 | 2020-09-30 | $799 | −$3,061 | −79.30% |
| Q2 2020 | 2020-06-30 | $799 | −$3,062 | −79.31% |
| Q1 2020 | 2020-03-31 | $799 | −$3,062 | −79.31% |
| Q3 2019 | 2019-09-30 | $3,860 | −$584 | −13.14% |
| Q2 2019 | 2019-06-30 | $3,861 | −$584 | −13.14% |
| Q1 2019 | 2019-03-31 | $3,861 | −$1,400 | −26.61% |
| Q3 2018 | 2018-09-30 | $4,444 | −$2,649 | −37.35% |
| Q2 2018 | 2018-06-30 | $4,445 | −$2,647 | −37.32% |
| Q1 2018 | 2018-03-31 | $5,261 | −$1,832 | −25.83% |
| Q3 2017 | 2017-09-30 | $7,093 | −$1,143 | −13.88% |
| Q2 2017 | 2017-06-30 | $7,092 | −$1,742 | −19.72% |
| Q1 2017 | 2017-03-31 | $7,093 | $439 | +6.60% |
| Q3 2016 | 2016-09-30 | $8,236 | −$2,613 | −24.09% |
| Q2 2016 | 2016-06-30 | $8,834 | $4,420 | +100.14% |
| Q1 2016 | 2016-03-31 | $6,654 | $2,351 | +54.64% |
| Q3 2015 | 2015-09-30 | $10,849 | $7,520 | +225.89% |
| Q2 2015 | 2015-06-30 | $4,414 | $1,385 | +45.72% |
| Q1 2015 | 2015-03-31 | $4,303 | $1,274 | +42.06% |
| Q3 2014 | 2014-09-30 | $3,329 | −$1,913 | −36.49% |
| Q2 2014 | 2014-06-30 | $3,029 | −$2,213 | −42.22% |
| Q1 2014 | 2014-03-31 | $3,029 | −$2,212 | −42.21% |
| Q3 2013 | 2013-09-30 | $5,242 | — | — |
| Q2 2013 | 2013-06-30 | $5,242 | — | — |
| Q1 2013 | 2013-03-31 | $5,241 | — | — |
Lipocine depreciation and amortization trends
Over the last five fiscal years, Lipocine's depreciation and amortization increased from $3,554 to $60,782, a change of $57,228. The latest reported quarter, Q2 2026, shows $14,648.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lipocine source filings ↗